Navigation Links
InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
Date:5/6/2009

TEL AVIV, Israel, May 6 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the iMOS registry. MGuard(TM) was successfully implanted at the General University Hospital in Prague; the procedure was performed by Dr. Jan Horak.

InspireMD plans to enroll 1000 'real world' Mguard(TM) patients. The registry, which is a post market study, will be conducted in Europe, Asia and South America. Data from the registry, an unselected heterogeneous population, will be used to support data from other clinical studies.

The first patient in the iMOS registry was a 54 year old male treated for acute myocardial infarction (STEMI) caused by a thrombus occluding the LAD artery. MGuard(TM) was successfully delivered and the patient was released from the hospital after a few days with no complications. Dr. Horak stated: "I feel MGuard(TM) offers enhanced safety during the procedure by preventing defragmentation of the thrombus. I look forward to seeing good clinical results for both the one-month and the six-month follow periods."

Mr. Eli Bar CTO and VP R&D stated: "The iMOS registry is very important for us in order to understand the clinical performance of MGuard(TM) and to be able to analyze special patient subgroups and modes of use of the MGuard(TM). Currently the MGuard(TM) is mostly used in AMI, SVG, and thrombus containing lesions. We hope that the iMOS registry will give us a wider perspective on its use."

Dr. Alexandre Abizaid, one of the principal investigators of the iMOS registry commented: "We are having a very positive experience with the MGuard(TM). The iMOS is going to broaden our understanding of the MGuard(TM) performance in larger and less homogenous populations."

Currently, two clinical trials with Mguard(TM) are underway. The GUARD Trial (MGuard in SVG and Native Coronaries Trial) is being conducted in Brazil, where the Principal Investigator is Dr. Alexandre Abizaid and the MAGICAL Trial (MGuard in Acute Myocardial Infarction Study) in Poland with Dr. Dariusz Dudek as Principal Investigator. The MAGICAL trial will include 60 STEMI patients, and its primary endpoints are complete ST segment resolution and restoration of flow through the occluded artery. New results from the MAGICAL and the GUARD studies are expected during the EUROPCR '09 in May in Barcelona.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without effecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.

The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis.

In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures. For further information visit http://www.inspire-md.com

    Contact:

    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    jonina@inspire-md.com



'/>"/>
SOURCE InspireMD
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):